NUE vs EMR

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 22, 2026

NUE

31.3
AI Score
VS
EMR Wins

EMR

69.7
AI Score

Investment Advisor Scores

NUE

31score
Recommendation
SELL

EMR

70score
Recommendation
STRONG BUY

AI Analyst Insights

Detailed Metrics Comparison

Metric NUE EMR Winner
Forward P/E 11.5075 20.8333 NUE
PEG Ratio 5.2129 1.728 EMR
Revenue Growth 23.0% 7.0% NUE
Earnings Growth 93.8% 23.0% NUE
Tradestie Score 31.3/100 69.7/100 EMR
Profit Margin 8.0% 13.8% EMR
Beta 1.00 1.00 Tie
AI Recommendation SELL STRONG BUY EMR

Relative Price Performance (Last 90 Days)

NUE 1M: -9.3% · 3M: +6.9% EMR 1M: +8.1% · 3M: +13.8%

Current Technical Phase

NUE

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 41

RSI (14): 40.8 · Price: $239.39

EMR

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (3.6% over 20 days), RSI 62

RSI (14): 62.0 · Price: $161.03

Fundamentals Snapshot

Metric NUE EMR
Market Cap — —
Forward P/E 11.9 21.8
Trailing P/E 18.9 34.4
Revenue (TTM) — —
Revenue Growth 0.2% 0.1%
Gross Margin 0.2% 0.5%
Operating Margin 0.2% 0.3%
EPS 12.39 4.51
Dividend Yield 0.01% 0.01%

Frequently Asked Questions

Based on our detailed analysis, EMR is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.